Penetrance vs. Expressivity: How Genes Determine Probability and Severity

Consider a standard light switch and a dimmer dial. A simple Mendelian genetic trait operates like the standard switch: if the genetic wiring is present, the light turns on, and the trait is expressed identically in everyone who carries it.

But for the vast majority of human traits and genetic conditions, inheritance is not a simple binary. It relies on 2 distinct mechanisms: one that determines whether the light turns on at all, and another that controls how intensely it shines. In the language of genetics, these 2 mechanisms are known as penetrance and expressivity.[1][3]

Penetrance is the probability of expression. It is a population-level metric that measures the proportion of individuals carrying a specific genetic variant who actually exhibit the associated physical trait or disease, known as the phenotype. According to Lumen Learning, "Penetrance refers to the probability of a gene or trait being expressed."

If 80 out of 100 people carrying a specific mutation develop the associated condition, the gene has an 80 percent penetrance rate. If every single person who inherits the mutated gene develops the condition, the gene is said to have complete, or 100 percent, penetrance.[3][4]

Huntington's disease is a classic example of 100 percent penetrance; anyone who inherits the expanded mutation will eventually develop the disease if they live long enough. However, many genetic variants exhibit incomplete, or reduced, penetrance. In these cases, a person can carry the dominant disease-causing allele but never show any signs of the condition.

For example, mutations in the BRCA1 or BRCA2 genes significantly increase the risk of developing breast and ovarian cancers, but the penetrance is not 100 percent. Some individuals with the mutation will develop cancer, while others will not, making it a probabilistic risk rather than a guaranteed outcome.[1][4]

Expressivity, on the other hand, measures the degree or severity of the phenotype once the trait is actually expressed. If penetrance asks whether the trait appeared, expressivity asks how severe it is. A 2021 clinical overview by MedlinePlus Genetics defines it clearly: "Variable expressivity refers to the range of signs and symptoms that can occur in different people with the same genetic condition."

Variable expressivity means that individuals with the exact same genetic mutation can present with a wide range of signs and symptoms. The condition is present in all of them, but it looks different from person to person.[1][3]

Marfan syndrome, a connective tissue disorder caused by mutations in the FBN1 gene, is a textbook example of variable expressivity. Two family members might inherit the identical FBN1 mutation, but one might only experience mild symptoms, such as being unusually tall with long, slender fingers. The other family member might develop life-threatening cardiovascular complications, such as an aortic aneurysm. The gene is fully penetrant—both individuals have the syndrome—but the expressivity varies dramatically.[1]

A single genetic condition can simultaneously exhibit both incomplete penetrance and variable expressivity. Polydactyly, the condition of having extra fingers or toes, is often caused by a dominant allele. Yet, not everyone who inherits the allele develops extra digits, demonstrating incomplete penetrance. Among those who do develop them, the extra digit might be a fully functional finger in one person, and a tiny, non-functional stub in another, demonstrating variable expressivity.[3]

The mechanisms driving these variations are complex and often poorly understood, but they generally fall into 3 categories: modifier genes, epigenetic factors, and environmental influences. Modifier genes are other genes in a person's genome that can alter the expression of the primary disease-causing gene, either dampening its effects or exacerbating them. Because every individual has a unique genetic background, these modifier genes create a unique environment for the mutation to operate within.[2][3]

Epigenetic factors—chemical modifications to DNA that turn genes on or off without changing the underlying sequence—also play a critical role in determining how a gene is expressed. The 2025 edition of the Merck Manual notes that these epigenetic modifications can be influenced by age, diet, and lifestyle, bridging the gap between a person's genetic code and their physical reality.

Environmental factors, ranging from chemical exposure to diet and stress, can further interact with a genetic variant to suppress or trigger its expression. As MedlinePlus Genetics notes, "Reduced penetrance probably results from a combination of genetic, environmental, and lifestyle factors, many of which are unknown."[1][2]

Understanding the distinction between these 2 concepts is crucial for clinical diagnosis and genetic counseling. When a patient tests positive for a disease-causing mutation, the immediate question is often what will happen to them. If the condition has reduced penetrance, the geneticist must explain that the mutation confers a risk, not a certainty. If the condition has variable expressivity, the geneticist must explain that even if the disease develops, its severity cannot be perfectly predicted from the DNA sequence alone.[1][4]

As genomic sequencing becomes more common in routine medical care, the concepts of penetrance and expressivity are moving from academic textbooks into everyday medical decisions. They serve as a reminder that DNA is not a rigid blueprint, but rather a set of probabilities and potentials. The presence of a gene is only the first step; the final outcome depends on a complex interplay of genetic background, environment, and chance.[5]